Anthracycline-related cardiomyopathy is of concern in children treated for acute myeloid leukemia (AML). Risk is dose-dependent, increasing with higher doses. We aim to highlight the risk of early-onset cardiotoxicity with low-cumulative anthracycline dose in a young Omani boy with AML. We conclude in the presence of other known risk factors for cardiac dysfunction, there is probably no risk-free anthracycline dose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1047951120003960 | DOI Listing |
Publication Analysis
Top Keywords
young omani
8
acute myeloid
8
anthracycline dose
8
anthracycline-related acute
4
acute cardiotoxicity
4
cardiotoxicity young
4
omani patient
4
patient acute
4
myeloid leukaemia
4
leukaemia anthracycline-related
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!